Audentes Therapeutics (BOLD)

38.08 +1.62 (4.44%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/6/19 *Est.)

Latest Headlines

Form 4 Audentes Therapeutics, For: Jul 15 Filed by: Conner Edward R. July 17, 2019 4:27 PM - SEC Filing Form 3 Audentes Therapeutics, For: Jul 15 Filed by: Conner Edward R. July 17, 2019 4:25 PM - SEC Filing Form 8-K Audentes Therapeutics, For: Jun 28 June 28, 2019 4:01 PM - SEC Filing Form 4 Audentes Therapeutics, For: Jun 24 Filed by: LANGE LOUIS G June 26, 2019 4:08 PM - SEC Filing Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 7, 2019 6:00 PM - PR NewsWire Form 4 Audentes Therapeutics, For: Jun 05 Filed by: PRASAD SUYASH June 7, 2019 4:43 PM - SEC Filing Form 4 Audentes Therapeutics, For: Jun 05 Filed by: Patterson Matthew R June 7, 2019 4:43 PM - SEC Filing Form 4 Audentes Therapeutics, For: Jun 05 Filed by: Holles Natalie C. June 7, 2019 4:42 PM - SEC Filing Form 4 Audentes Therapeutics, For: Jun 05 Filed by: Soloway Thomas P June 7, 2019 4:41 PM - SEC Filing Form 8-K Audentes Therapeutics, For: Jun 07 June 7, 2019 4:30 PM - SEC Filing Form 8-K Audentes Therapeutics, For: May 29 May 29, 2019 4:05 PM - SEC Filing Audentes Therapeutics (BOLD) Announces Edward Conner, M.D. appointed as SVP and Chief Medical Officer May 29, 2019 4:02 PM - StreetInsider Audentes Therapeutics Announces Changes to Senior Management Team May 29, 2019 4:01 PM - PR NewsWire Scientist.com Partners With 5AM Ventures to Create an R&D Marketplace for Biotech Startups May 29, 2019 7:55 AM - BizWire Form 4 Audentes Therapeutics, For: May 13 Filed by: PRASAD SUYASH May 15, 2019 5:09 PM - SEC Filing Form S-8 Audentes Therapeutics, May 13, 2019 6:04 AM - SEC Filing Audentes Therapeutics to Participate in the Bank of America Merrill Lynch 2019 Health Care Conference May 8, 2019 8:00 AM - PR NewsWire Audentes Therapeutics (BOLD) PT Raised to $47 at BMO Capital May 8, 2019 7:32 AM - StreetInsider Form 10-Q Audentes Therapeutics, For: Mar 31 May 8, 2019 6:42 AM - SEC Filing Audentes Therapeutics (BOLD) Misses Q1 EPS by 24c May 7, 2019 4:30 PM - StreetInsider Form 8-K Audentes Therapeutics, For: May 07 May 7, 2019 4:06 PM - SEC Filing Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update May 7, 2019 4:01 PM - PR NewsWire Form 8-K Audentes Therapeutics, For: May 01 May 1, 2019 2:17 PM - SEC Filing Audentes Therapeutics (BOLD) Presents New Positive Data from ASPIRO Phase 1/2 Clinical Trial of AT132 for XLMTM May 1, 2019 2:16 PM - StreetInsider Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular Myopathy, at 22nd Annual Meeting of the American Society of Gene and Cell Th May 1, 2019 2:15 PM - PR NewsWire Audentes Therapeutics to Release First Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, May 7, 2019 April 30, 2019 8:00 AM - PR NewsWire Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 26, 2019 6:00 PM - PR NewsWire Form DEFA14A Audentes Therapeutics, April 26, 2019 4:38 PM - SEC Filing Form DEF 14A Audentes Therapeutics, For: Jun 07 April 26, 2019 4:33 PM - SEC Filing Audentes Therapeutics (BOLD) PT Lowered to $32 at Citi April 26, 2019 7:43 AM - StreetInsider Citi Downgrades Audentes Therapeutics (BOLD) to Sell April 26, 2019 6:01 AM - StreetInsider Audentes Therapeutics Announces Launch of New State-of-the-Art Internal cGMP Plasmid Manufacturing Facility April 23, 2019 8:00 AM - PR NewsWire Full Article List